返回主页 >>   
                             
 

 BRC1503 - 乳腺癌组织芯片

 
批号 芯粒 大小 厚度 排列 质检/质控 价格 下载
 BRC1503 150 1.1mm 4um 15X10 H&E, IHC 抗纤维蛋白/细胞角蛋白 查询 PDF文件
订购: sales@fanpu.com                         电话: 0773-3119018
 
适用于:免疫组化或原位杂交对蛋白或RNA分子在多种乳腺癌组织与正常、炎症等组织表达差异性分析。

描述:150芯,包括70例不同类型乳腺癌(70例病例完全不同于BRC1501、BRC1502),5例正常及炎症等组织,双芯布阵。组织经10%中性福尔马林缓冲液固定24小时,用统一标准的方法加工。组织芯片被固定于美国进口的Superfrost Plus 或APES处理的Superfrost 防脱载玻片上。在4°C保存。从发货日开始所有芯片均有6个月的保质期。每片芯片的完整率大于>90%。
 
 

位置

年龄

性别

病理分类

病理分级

TNM

ER

PR

Ki67

A1,B1

26

正常

 

 

++, 5%

++, 2%

++~+++, 2%

A2,B2

45

乳腺腺病

 

 

+, 5%

++, 2%

++, 1%

A3,B3

35

乳腺腺病

 

 

++, 50%

++, 5%

++~+++, 5%

A4,B4

23

纤维腺瘤

 

 

++, 30%

++, 60%

++, 2%

A5,B5

40

纤维囊性乳腺病

 

 

+~++, 50%

++, 30%

-

A6,B6

48

浸润性导管癌

II

T2N0M0

++, 60%

++, 50%

-

A7,B7

42

浸润性导管癌

II

T2N0M0

++~+++, 80%

++~+++, 50%

++, 5%

A8,B8

32

浸润性导管癌

 

T2N0M0

++~+++, 80%

++, 60%

++~+++, 5%

A9,B9

48

浸润性导管癌

III

T2N0M0

++~+++, 60%

++~+++, 15%

++, 5%

A10,B10

44

浸润性导管癌

I

T2N0M0

++~+++, 80%

++, 50%

++, 2%

A11,B11

50

浸润性导管癌

III

T2N0M0

++, 50%

++, 2%

-

A12,B12

63

浸润性导管癌

III

T2N0M0

++~+++, 60%

-

+~++, 2%

A13,B13

42

浸润性小叶癌

I~II

T2N0M0

+, 5%

++, 50%

-

A14,B14

46

浸润性导管癌

III

T2N0M0

-

-

++~+++, 70%

A15,B15

34

浸润性小叶癌

I

T2N0M0

-

++, 1%

+~++, 2%

C1,D1

53

浸润性导管癌

III

T2N0M0

+++, 70%

-

++~+++, 5%

C2,D2

25

小叶原位癌

II

TisN0M0

++~+++, 50%

+~++, 30%

++, 5%

C3,D3

45

浸润性小叶癌

I~II

T2N0M0

++, 80%

-

+, 2%

C4,D4

44

浸润性导管癌

I

T2N0M0

-

-

+, 2%

C5,D5

38

导管癌

I

T2N0M0

+~++, 30%

++, 30%

-

C6,D6

70

浸润性导管癌

I~II

T2N0M0

+++, 90%

++~+++, 90%

++, 2%

C7,D7

56

浸润性导管癌

III

T2N0M0

-

-

+++, 5%

C8,D8

52

浸润性导管癌

III

TisN0M0

-

-

+++, 5%

C9,D9

68

浸润性导管癌

III

T1N0M0

++~+++, 90%

-

++~+++, 20%

C10,D10

68

浸润性导管癌

I~II

T3N2M0

+~++, 80%

-

++, 10 %

C11,D11

46

浸润性导管癌

I~II

T2N0M0

+++, 80%

++~+++, 80%

-

C12,D12

52

浸润性导管癌

II~III

T2N0M0

-

-

++~+++, 10%

C13,D13

59

浸润性导管癌

I~II

T2N0M0

+, 50%

-

++, 5%

C14,D14

39

浸润性导管癌

II~III

T2N0M0

+++, 60%

+, 5%

++, 2%

C15,D15

40

浸润性导管癌

II~III

T2N2M0

++~+++, 50%

-

++, 5%

E1,F1

40

浸润性导管癌

II

T2N0M0

+~++, 80%

+, 2%

++~+++, 15%

E2,F2

60

浸润性导管癌

I~II

T2N0M0

+++, 80%

+, 1%

++, 5%

E3,F3

50

浸润性导管癌

II

T2N0M0

++, 80%

-

++, 5%

E4,F4

45

浸润性导管癌

I~II

T2N0M0

+~++, 60%

++~+++, 60%

++~+++, 15%

E5,F5

46

浸润性导管癌

II

T2N1M0

++, 30%

++~+++, 30%

-

E6,F6

39

浸润性导管癌

I~II

T2N1M0

+++, 80%

-

++, 10%

E7,F7

48

浸润性导管癌

III

T2N0M0

++~+++, 60%

++~+++, 60%

++, 10%

E8,F8

41

浸润性导管癌

I~II

T2N0M0

++, 50%

++, 50%

++, 2%

E9,F9

61

导管原位癌

III

T2N0M0

+++, 80%

++, 20%

-

E10,F10

86

浸润性大汉腺癌

II~III

T2N0M0

-

-

++, 5%

E11,F11

34

浸润性导管癌

III

T2N0M0

-

-

++, 8%

E12,F12

64

浸润性导管癌

II

T2N0M0

+~++, 10%

-

++~+++, 10%

E13,F13

35

浸润性小叶癌

II~III

T2N1M0

+~++, 10%

 -

++~+++, 5%

E14,F14

44

浸润性管状癌

I~II

T2N1M0

++, 80%

++, 60%

++~+++, 10%

E15,F15

54

浸润性导管癌

III

T2N0M0

-

-

++~+++, 15%

G1,H1

40

浸润性导管癌

II

T2N0M0

+~++, 50%

++, 60%

++, 2%

G2,H2

58

浸润性导管癌

 

T2N1M0

++~+++, 60%

-

++, 5%

G3,H3

55

浸润性导管癌

 

T2N1M0

-

-

++, 10%

G4,H4

74

浸润性导管癌

I~II

T2N0M0

+++, 90%*

++~+++, 60%

++, 2%

G5,H5

50

浸润性导管癌

I~II

T2N0M0

-

-

++, 10%

G6,H6

53

浸润性导管癌

I~II

T2N0M0

-

-

++, 10%

G7,H7

53

浸润性导管癌

II

T2N0M0

++~+++, 90%

+~++, 50%

++, 5%

G8,H8

71

浸润性导管癌

II

T4N0M0

-

-

++, 15%

G9,H9

48

浸润性导管癌

 

T2N0M0

++, 80%

+++, 90%*

-

G10,H10

43

浸润性导管癌

II

T2N0M0

++~+++, 80%

+~++, 50%

++, 5%

G11,H11

34

导管内癌

I~II

T2N0M0

++~+++, 80%

+~++, 50%

++, 10%

G12,H12

52

浸润性导管癌

III

T2N0M0

-

-

++, 5%

G13,H13

55

浸润性导管癌

II

T2N1M0

++~+++, 60%

-

++, 30%

G14,H14

54

浸润性导管癌

I

T2N0M0

-

-

++~+++, 20%

G15,H15

40

浸润性导管癌

 

T2N1M0

++~+++, 30%

+~++, 30%

-

I1,J1

34

浸润性导管癌

III

T2N0M0

+~++, 60%

++, 60%

+~++, 5%

I2,J2

59

浸润性导管癌

II~III

T2N0M0

+++, 80%

-

+~++, 5%

I3,J3

76

浸润性导管癌

III

T2N0M0

-

-

++, 20%

I4,J4

39

浸润性导管癌

III

T2N0M0

-

-

++, 2%

I5,J5

33

浸润性导管癌

 

T2N1M0

-

-

-

I6,J6

52

浸润性导管癌

I~II

T2N0M0

-

-

++, 2%

I7,J7

72

浸润性导管癌

III

T4N0M0

++~+++, 60%

+~++, 15%

++, 10%

I8,J8

35

浸润性导管癌

 

T3N1M0

+~++, 5%

+~++, 5%

++, 5%

I9,J9

60

浸润性导管癌

III

T2N0M0

+++, 80%

++~+++, 80%

++, 2%

I10,J10

58

 

浸润性导管癌

II

T2N0M0

++, 60%

+~++, 60%

++, 5%

I11,J11

53

浸润性导管癌

I~II

T3N0M0

++, 10%

-

-

I12,J12

52

浸润性小叶癌

I~II

T2N0M0

++, 50%

++, 1%

++, 5%

I13,J13

71

浸润性导管癌

II~III

T1N0M0

+++, 90%*

++~+++, 50%

++, 5%

I14,J14

70

浸润性导管癌

II

T1N0M0

+++, 90%

++, 60%

++, 5%

I15,J15

44

导管内癌

II

T2N0M0

-

-

 

 
 
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
所有产品 | 联系我们 | 版权声明
版权所有 © 桂林泛谱生物技术有限公司 桂林市高新区留学人员创业园B座202室 541004